K Number
K020071
Device Name
VIRIDIS DERMA LASER
Manufacturer
Date Cleared
2002-04-05

(86 days)

Product Code
Regulation Number
878.4810
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Viridis Derma laser is intended for photocoagulation of pigmented lesions in dermatology. These include the following specific applications: Benign Vascular Lesions, Facial Telangiectasias, Port Wine Stains, Café au-lait, Erythrosis, Benign Pigmented Lesions, Cuperosis, Senile Lentigo, Keratoses, Hemangiomas (spider and cherry/strawberry), Dermatosis Papulosis Nigra (DPN), Leg Telangiectasia - only as a complement to sclerotherapy and for small superficial red vessels.
Device Description
The Viridis Derma frequency doubled Nd:YAG laser emits a beam of coherent light at 532 microns.
More Information

Not Found

No
The summary describes a laser device for photocoagulation and does not mention any AI or ML capabilities, image processing, or data-driven features.

Yes
The device is intended for the photocoagulation of various benign vascular and pigmented lesions, which are therapeutic applications.

No
The document states that the device is intended for "photocoagulation of pigmented lesions," indicating a therapeutic rather than diagnostic purpose.

No

The device description explicitly states it is a "frequency doubled Nd:YAG laser," which is a hardware component that emits a beam of light. This is not a software-only device.

No, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information about a person's health. These tests are performed outside of the body.
  • Viridis Derma Laser Function: The Viridis Derma laser is used for photocoagulation of pigmented lesions on the body. It directly interacts with the patient's tissue using light energy.
  • Lack of Sample Analysis: The description does not mention any analysis of biological samples. The device is applied directly to the skin.

Therefore, based on the provided information, the Viridis Derma laser is a therapeutic device used for dermatological procedures, not an in vitro diagnostic device.

N/A

Intended Use / Indications for Use

The Viridis Derma laser is intended for photocoagulation of pigmented lesions in dermatology.

These include the following specific applications:
Benign Vascular Lesions
Facial Telangiectasias
Port Wine Stains
Café au-lait
Erythrosis
Benign Pigmented Lesions
Cuperosis
Senile Lentigo
Keratoses
Hemangiomas (spider and cherry/strawberry)
Dermatosis Papulosis Nigra (DPN)
Leg Telangiectasia - only as a complement to sclerotherapy and for small superficial red vessels

Product codes

GEX

Device Description

The Viridis Derma frequency doubled Nd:YAG laser emits a beam of coherent light at 532 microns.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

The Viridis Derma laser will be labeled as a prescription device as follows: CAUTION: Federal (US) law restricts the use of this device to licensed professionals.
CAUTION: Federal (US) law restricts this device to sale by or on the order of a physician.

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

None required.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K001784, K970667, K983020, K964074, K981447, K003202

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.

(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.

0

APR = 5 2002

K 020071

SECTION 10

510(k) SUMMARY

This 510(k) summary of safety and effectiveness for the Viridis Derma (frequency doubled I MD > ( ( ) sa is submitted in accordance with the requirements of SMDA 1990 and follows Office of Device Evaluation guidance concerning the organization and content of a 510(k) summary.

Applicant: QUANTEL MEDICAL

Address:

QUANTEL MEDICAL 21 rue Newton ZI du BREZET 63039 Clermont-Ferrand Cedex 2 FRANCE +33 (0)473 745 745 +33 (0)473 745 700 (Fax)

  • Mr. Jean Abascal Contact Person: Regulatory Affairs Manager (+33) 169 29 17 25 (+33) 169 29 17 29 (Fax)
    Preparation Date: December 2001 (of the Summary)

Viridis Derma Device Name:

Frequency Doubled Nd: Y AG Surgical Laser Common Name:

Laser surgical instrument for use in general and plastic surgery and in Classification dermatology (see: 21 CFR 878.4810). Name: Product Code: GEX Panel: 79

  • The Viridis Laser (K001784): Nuvo-Lase 660 Laser System (K970667) Predicate device COMPACT KTP Laser (K983020); DioLite 532 Laser System (K964074); Nidek Dio-Lite 60 Laser System (K981447); Altus Family of CoolGlide Aesthetic Lasers (K003202)
    Device description: The Viridis Derma frequency doubled Nd:YAG laser emits a beam of coherent light at 532 microns.

1

The Viridis Derma laser is intended for photocoagulation of pigmented Indications: lesions in dermatology.

These include the following applications:

Facial Telangiectasias Benign Vascular Lesions Café au-lait Port Wine Stains Benign Pigmented Lesions Erythrosis Senile Lentigo Cuperosis Hemangiomas (spider and cherry/ Keratoses Dermatosis Papulosis Nigra (DPN) strawberry) Leg Telangiectasia - only as a complement to sclerotherapy and for small superficial red vessels

The Viridis Derma laser will be labeled as a prescription device as follows:

CAUTION: Federal (US) law restricts the use of this device to licensed professionals

Performance Data: None required.

CONCLUSION:

Based on the information in the notification Quantel Medical concludes that the Viridis Derma frequency doubled Nd: YAG laser is substantially equivalent to the Viridis laser and to other cited legally marketed predicates, under the conditions of intended use (above).

2

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the words "Public Health Service" in a simple, sans-serif font. The text is black and appears to be on a white background. The words are arranged on a single line, with "Public Health" appearing before "Service".

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ouantel Medical c/o Mr. Roger W. Barnes 342 Sunset Bay Road Hot Springs, AR 71913

APR = 5 2002

Re: K020071

Trade/Device Name: Viridis Derma Laser Regulation Number: 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: II Product Code: GEX Dated: January 7, 2002

Received: January 9, 2002

Dear Mr. Barnes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

3

Page 2 - Mr. Roger W. Barnes

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Muriam C. Provost

For Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

SECTION 7

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): KO2007

Device Name:_Viridis Derma (Frequency doubled Nd: YAG laser)

Indications for Use Statement:

The Viridis Derma laser is intended for photocoagulation of pigmented lesions in dermatology.

These include the following specific applications:

Benign Vascular LesionsFacial Telangiectasias
Port Wine StainsCafé au-lait
ErythrosisBenign Pigmented Lesions
CuperosisSenile Lentigo
KeratosesHemangiomas (spider and cherry/
strawberry)
Dermatosis Papulosis Nigra (DPN)Leg Telangiectasia - only as a complement to sclerotherapy and for small superficial
red vessels

The Viridis Derma laser is labeled as a prescription device as follows:

CAUTION: Federal (US) law restricts this device to sale by or on the order of a physician.

Musiaml-Provost

(Division Sign-Off) Division of General, Restorative and Neurological Devices

510(k) Number K020671

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation

Prescription Use (Per 21 CFR 801.109)

OR

Over-The Counter Use _________________________________________________________________________________________________________________________________________________________